Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics
- 1 October 1997
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 350 (9083), 995-999
- https://doi.org/10.1016/s0140-6736(97)03211-x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Salmeterol tachyphylaxis in steroid treated asthmatic subjects.Thorax, 1996
- Beta 2 adrenoceptor polymorphisms: are they clinically important?Thorax, 1996
- Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients.Thorax, 1995
- Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype.Journal of Clinical Investigation, 1995
- Implications of Genetic Variability of Human β2-adrenergic Receptor StructurePulmonary Pharmacology, 1995
- Risks of Salmeterol?New England Journal of Medicine, 1994
- Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterolRespiratory Medicine, 1994
- Respiratory arrests in young asthmatics on salmeterolRespiratory Medicine, 1993
- Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.BMJ, 1993
- Long-Term Effects of a Long-Acting β2-Adrenoceptor Agonist, Salmeterol, on Airway Hyperresponsiveness in Patients with Mild AsthmaNew England Journal of Medicine, 1992